News for Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

On July 25, 2025, Goldman Sachs analyst Richard Law initiated coverage on Arcutis Biotherapeutics (ARQT), assigning a "Neutral" rating. This marks the first rat

Goldman Sachs has begun its analysis of Arcutis Biotherapeutics (ARQT), assigning the company a Neutral rating and setting a price target of $18. The brokerage

Arcutis Biotherapeutics (ARQT) to announce Q2 2025 financial results on August 6, 2025, after market close. Conference call and webcast scheduled for 4:

WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ( ARQT), a commercial-stage biopharmaceutical company focused on dev

Summary On July 3, 2025, Arcutis Biotherapeutics Inc (ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced the gran

WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ( ARQT), a commercial-stage biopharmaceutical company focused on dev

WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis’ common stock to two newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

On July 1, 2025, Howard Welgus, a Director at Arcutis Biotherapeutics Inc (ARQT), sold 9,208 shares of the company. Following this transaction, the insider now

Arcutis Biotherapeutics (ARQT) has announced that its ZORYVE cream 0.15% earned a robust endorsement in the updated management guidelines for adult atopic derma

Arcutis stock sees a 5% dip; Zoryve gains 4th approval, boosting sales. Cash flow breakeven expected by 2026. Read more on ARQT stock here.

On June 18, 2025, Howard Welgus, a Director at Arcutis Biotherapeutics Inc (ARQT), sold 10,139 shares of the company. Following this transaction, the insider no

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the first child in its Phase 2 clinical trials called INTEGUMENT-INFANT. The trial aims to test the safety and tolerability of an investigational topical treatment, ZORYVE cream 0.05% in infants aged […]

Arcutis Biotherapeutics is a standout in biotech with FDA-approved ZORYVE and strong potential. See why we recommend a buy on ARQT stock.

Arcutis Biotherapeutics (ARQT) has initiated a Phase 2 open-label clinical trial named INTEGUMENT-INFANT. This study marks the enrollment of its first infant pa

Summary Arcutis Biotherapeutics Inc (ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced on May 29, 2025, that it

WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ( ARQT), a commercial-stage biopharmaceutical company focused on deve

On May 23, 2025, analyst Serge Belanger from Needham provided an updated analysis on Arcutis Biotherapeutics (ARQT), reiterating a 'Buy' rating for the stock. T